1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine maleate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine maleate
• 英文别名: 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine maleate；(Z)-but-2-enedioic acid;1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine
• 化学式: C₄H₄O₄*C₁₈H₂₂N₂S
• 分子量: 414.525
• InChiKey: CQSVBPFCYHGUJN-BTJKTKAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.58
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  沃替西汀氢溴酸盐 在 sodium hydroxide 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 4.25h， 生成 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine maleate
  参考文献：
  名称：

  WO2007/144005

  摘要：

  公开号：
• 作为试剂：
  描述：

  沃替西汀 、 顺丁烯二酸 在 乙醚 、 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine maleate 、 乙酸乙酯 、 甲醇 作用下， 以 乙酸乙酯 为溶剂， 反应 54.08h， 以1-[2-(2,4-Dimethylphenylsulfanyl)-phenyl]piperazine Maleate was isolated in 0.9 gram (69%)的产率得到1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine maleate
  参考文献：
  名称：

  1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment

  摘要：

  本披露涉及一种制备1-[2-(2,4-二甲基苯基硫基)-苯基]哌嗪或其盐的过程。

  公开号：

  US20140371453A1

文献信息

• 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition
  申请人：Moore Nicholas

  公开号：US08664225B2

  公开（公告）日：2014-03-04

  The use of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine in the treatment of pain and residual symptoms in depression is provided.

  提供使用1-[2-(2,4-二甲基苯基磺酰基)苯基]哌嗪治疗疼痛和抑郁症残留症状的方法。
• 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
  申请人：H. Lundbeck A/S

  公开号：US08969355B2

  公开（公告）日：2015-03-03

  This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

  本公开涉及一种治疗从以下疾病组中选择的方法，包括情感障碍、抑郁症、重性抑郁障碍、焦虑、广泛性焦虑障碍、社交焦虑障碍、强迫症、惊恐障碍和惊恐发作。该方法包括向需要治疗的患者施用化合物I或其药学上可接受的盐的治疗有效量，其中化合物I是1-[2-(2,4-二甲基苯基硫基)-苯基]哌嗪。
• 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
  申请人：Bang-Andersen Benny

  公开号：US08722684B2

  公开（公告）日：2014-05-13

  1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

  1-[2-(2,4-二甲基苯基硫酰基)苯基]哌嗪在SERT、5-HT3和5-HT1A上表现出强大的活性，因此可能有助于治疗认知障碍，尤其是在抑郁患者中。
• Process for preparing 1-[2-(2,4-dimethylphenysulfanyl)-pheny]piperazine or pharmaceutically acceptable salt thereof
  申请人：H. Lundbeck A/S

  公开号：US09095588B2

  公开（公告）日：2015-08-04

  This disclosure relates to a process for the preparation of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a salt thereof. The process includes reacting compound II with compound III and compound IV in the presence of a solvent, a base and a palladium catalyst. R, R′, X1, and X2 in the formulas above are defined in the Specification.

  本公开涉及一种制备1- [2-（2,4-二甲基苯基硫基）-苯基]哌嗪或其盐的过程。该过程包括在溶剂，碱和钯催化剂的存在下，将化合物II与化合物III和化合物IV反应。上述公式中的R，R'，X1和X2在规范中有定义。
• Process for preparing 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salt thereof
  申请人：H. Lundbeck A/S

  公开号：US09101626B2

  公开（公告）日：2015-08-11

  This disclosure relates to a process for the preparation of 1-[2-(2,4-dimethylphenylsulfanyl) -phenyl]piperazine or a pharmaceutically acceptable salt thereof. The process includes reacting compound II with compound III and compound IV in the presence of a solvent, a base and a palladium catalyst. R, R′, Xi, and X2 in the formulas above are defined in the Specification.

  本公开涉及一种制备1-[2-(2,4-二甲基苯基硫基)-苯基]哌嗪或其药学上可接受的盐的过程。该过程包括在溶剂、碱和钯催化剂的存在下，将化合物II与化合物III和化合物IV反应。上述公式中的R、R'、Xi和X2在说明书中有定义。